Egetis Therapeutics AB (publ)
STO:EGTX

Watchlist Manager
Egetis Therapeutics AB (publ) Logo
Egetis Therapeutics AB (publ)
STO:EGTX
Watchlist
Price: 6.65 SEK 0.91%
Market Cap: 2.4B SEK
Have any thoughts about
Egetis Therapeutics AB (publ)?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-8.7
Current
-8.3
Median
4.2
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-8.7
=
Enterprise Value
2.3B SEK
/
EBITDA
-263.7m SEK
All Countries
Close
Market Cap EV/EBITDA
SE
Egetis Therapeutics AB (publ)
STO:EGTX
2.4B SEK -8.7
FR
Pharnext SCA
OTC:PNEXF
6T USD -220 185.9
US
Abbvie Inc
NYSE:ABBV
318.1B USD 15.5
US
Amgen Inc
NASDAQ:AMGN
142.2B USD 16.1
US
Gilead Sciences Inc
NASDAQ:GILD
117.1B USD 10.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.2B USD 21.6
US
Epizyme Inc
F:EPE
94.1B EUR -513.1
AU
CSL Ltd
ASX:CSL
135.7B AUD 19.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD 15.4
US
Seagen Inc
F:SGT
39.3B EUR -58.6
NL
argenx SE
XBRU:ARGX
36.2B EUR -109.7
EBITDA Growth EV/EBITDA to Growth
SE
Egetis Therapeutics AB (publ)
STO:EGTX
Average EV/EBITDA: 16.5
Negative Multiple: -8.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -220 185.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.5
29%
0.5
US
Amgen Inc
NASDAQ:AMGN
16.1
62%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.3
16%
0.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.6
43%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -513.1 N/A N/A
AU
CSL Ltd
ASX:CSL
19.8
42%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.4
35%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.6 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -109.7 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-8.1
2-Years Forward
EV/EBITDA
-20.6
3-Years Forward
EV/EBITDA
13.9

See Also

Discover More